Contact Supplier

Contact Supplier

To get in touch with Bachem AG, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    Bachem showcasing well-stocked development pipeline at INTERPHEX Osaka

    news-releasesBachem AG
    February 16th 2021

    Bubendorf, Switzerland: –Peptide technology specialist Bachem will be a prominent presence atAsia’s leading exhibition for the pharmaceutical industry, INTERPHEX Week Osaka 2021.

    Bachem will be represented by its Japanese arm, Bachem Japan KK, who will participatein the online part of the event as a virtual exhibitor.

    INTERPHEX 2021 will also be staged as a physical expo at the INTEX Exhibition Center in Osaka, Japan’s largest pharmaceutical cluster. Both the physical and virtual events open on February 24, 2021.

    Comprehensive peptide manufacturing offers

    Bachem will be bringing compelling propositions and offers to both of INTERPHEX Week’s co-located exhibitions for pharmaceutical technologies.

    For INTERPHEX, the B2B trade show focusing on pharmaceutical manufacturing, the Bachem Japan team is ready to provide online advice on visitors detailed needs for peptides and oligonucleotides and will show different ways of meeting API custom manufacturing needs.

    The team will present Bachem’s capacity to produce generic peptide APIs in quantities of hundreds of kilograms and small molecules in tens of tons per year and its record of over 80 DMF filings in the pipeline.

    “We will certainly be able to support the success of our clients’ projects from initiation, through all clinical development phases to commercial supply,” commented Satoshi Mashiko, Head of Business Development Asia, Bachem Japan KK.

    Impressive R&D pipeline

    The other co-located show, PharmaLab Expo Osaka, will focus on technologies for Pharma R&D and Drug Discovery. Here, too, Bachem will be available online to present a research and development pipeline that now contains more than 150 customer projects in preclinical and clinical phases.

    Over the past two years, several products in Phase III trials have received marketing authorization, with Phase II projects progressing to Phase III clinical trials. In addition, Bachem is strategically diversifying its technology platform to include the manufacture of therapeutic oligonucleotides and nucleic-acid-based medicine, with a full-service oligonucleotide manufacturing facility is being built at its global headquarters in Bubendorf, Switzerland.

    About Bachem

    The Swiss based Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of pepTides, oligonucleoTides and complex organic molecules as active pharmaceutical ingredients (APIs). A comprehensive catalog of innovative biochemicals for research and exclusive custom syntheses for research labs complete its service portfolio.

    With 50 years of experience, headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach and shows total commitment to quality, innovation and partnership to its customers worldwide.

    Under its banner Leading Partner in Tides, Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.

    Bachem has five production sites in the US, UK and Switzerland along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, and new chemical entities (NCEs) at preclinical, clinical and production scales.

    Further information at:

    About INTERPHEX Week Osaka 2021

    The INTERPHEX (International Pharmaceutical Expo) series unites leading single source events for biopharmaceutical and pharmaceutical manufacturing and processing solutions and technologies. Each expo showcases equipment, accessories and technologies while offering networking and peer-to-peer sharing opportunities, presentations and interactive demonstrations. INTERPHEX Japan is now the country’s largest B2B trade show for the pharmaceutical R&D and manufacturing sectors.

    INTERPHEX Week Osaka is a three-day hybrid event opening February 24, 2021, at the INTEX Osaka exhibition center. It will bring together two exhibitions for pharmaceutical technologies: INTERPHEX JAPAN (Manufacturing & Packaging), and PharmaLab Japan: formerly BIOtech Japan (Drug Discovery). The 2021 event will have more than 200 exhibitors on-site, making this one of the largest F2F events seen in the pharma industry since the start of the global coronavirus pandemic.

    To reflect COVID-19 safeguards, the event will be held partly online with the physical event subject to anti-coronavirus safeguards including entry testing, face coverings and physical distancing.

    The event is organized by Reed Exhibitions Japan, with further information at:


    Click on Bachem at INTERPHEX Week Osaka 2021 for more information.
    Click on API Products for further information.
    Click on Bachem Generic APIs to download brochure.
    Click on Bachem APIs to download flyer.
    Click on Bachems News to see latest News & Events.


    Bachem – Partner from Research to Marketed API

    Bachem showcasing well-stocked development pipeline at INTERPHEX Osaka

    INTERPHEX Week venue: INTEX Exhibition Center, Osaka

    Contact Bachem AG

    Simply fill out the form below to contact Bachem AG now.

    Send Bachem AG a Message